T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
about
Physical chemistry in a single live cell: confocal microscopy.Atezolizumab for the treatment of non-small cell lung cancer.Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.Signals that drive T follicular helper cell formation.PD1 signal transduction pathways in T cells.Co-stimulatory function in primary germinal center responses: CD40 and B7 are required on distinct antigen-presenting cells.PD-1 and CTLA4: Two checkpoints, one pathway?Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.Improving radiotherapy in cancer treatment: Promises and challenges.Cytomegalovirus (CMV) Epitope-Specific CD4(+) T Cells Are Inflated in HIV(+) CMV(+) Subjects.PD1 functions by inhibiting CD28-mediated co-stimulation.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Dynamic regulation of CD28 conformation and signaling by charged lipids and ions.Membrane Rafts in T Cell Activation: A Spotlight on CD28 Costimulation.In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase.Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner.Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy.Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors.Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.Immune checkpoint inhibitors: new strategies to checkmate cancer.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.The diverse functions of the PD1 inhibitory pathway.CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.Advances in immunotherapy for pediatric acute myeloid leukemia.Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.Inhibitors of the PD-1 Pathway in Tumor Therapy.Prior to Peripheral Tolerance, Newly Generated CD4 T Cells Maintain Dangerous Autoimmune Potential: Fas- and Perforin-Independent Autoimmunity Controlled by Programmed Death-1.Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
P2860
Q36367754-1E0E5CD1-B8CD-48C9-B90B-120EC5521C94Q38675969-FE56A2EE-01FC-486E-993B-F4EDFE491D57Q38916367-F5DE95DB-7ADE-4CDF-B5B7-C805C834C39FQ39382728-E23B7E7A-3E56-41A0-832B-C2D876A60EA9Q40062424-23BFC49D-1F69-4205-841B-BA55BEEE2D5CQ40109543-9AA2DC79-E1D6-470F-A783-350C2486C794Q40204056-DE5FB1AA-FE79-4248-92FE-E8184A96BDEEQ40236161-5E73D22B-D3BD-45E1-8DF2-AF203AC8175EQ40975860-31082805-FE4A-447A-986C-0D27115C3A8DQ41668880-910F48FD-59FF-465D-9A7F-C5E0DEEEDDC2Q41899048-0F0ED7FF-D11F-4A2F-95DA-FF690049A472Q41991727-C5F0879B-697D-4F22-AB9B-F21E3FCE213DQ42332962-75B04F97-0E65-4D19-A2A5-A262AFF4144AQ42369857-63FD5EC4-D9C2-47DF-A42D-6D6197A60DDBQ42517281-12949031-3941-439D-8544-A9E0F38A535EQ44479360-547C38CD-199A-466C-92E6-BCFA1E15629CQ46510592-D46F4346-807D-4F02-8C99-E267516878EDQ47113506-851ED109-D7DB-48AC-921F-3E8AFA4AAB24Q47120629-E5A0ED59-9881-4898-A24D-75F86A87A937Q47137043-822ACBBD-74BB-4DFD-8A3C-293C4DC22E24Q47194075-E0DFCFB2-D682-4BB0-81CF-6BF5FB1A7BBBQ47219905-3C3ADB96-0801-4B03-ACE0-9F39E5E4543CQ47223979-325A1B0A-01F4-4529-8596-4BDAB0C083EAQ47250902-DB50E8F4-B859-4566-977F-ACCB4084F6FEQ47325431-BE4BE487-8DF0-4DCF-9964-EAB7ED64B30EQ47325439-A0EB766B-221D-43CA-8BED-B2C0CEC4E298Q47372804-06CB0D02-47CB-4197-82E6-4450453CDF50Q47400647-CFA37896-A666-4F1F-B89F-FBB99E737E6FQ47563451-FE7D1C7F-67FB-4301-BBE0-D9CA7B8EB4EBQ47563512-E36E8685-18E6-4240-BE59-245CBC395EBFQ47593614-D12C39F8-9394-4932-B673-07C63ACA8288Q47666073-6D457DD1-4C48-4EE3-9829-4E09BEDD719FQ47678849-2775B53F-5306-4DFC-8205-970192DF3523Q47862082-669A8B9E-AEC3-4C4D-B764-288C2BD64278Q47930962-AE340C04-99B2-427E-B389-FBFA9D266ACCQ47986213-A5C6B45C-FBF6-4BB9-9312-F95F337789A0Q48293633-A1710AF6-59EA-4555-B8B7-F18245C41B25Q49170322-B21AEBFF-C24E-445F-B291-7F4B9C1E63E2Q49383236-C5F26C45-E799-48ED-8553-55F4A06AA9D0Q49835172-ACFD20E3-2AEA-4D9E-9D5F-D81A18A155AE
P2860
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
@en
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
@nl
type
label
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
@en
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
@nl
prefLabel
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
@en
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
@nl
P2093
P2860
P50
P356
P1433
P1476
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
@en
P2093
Dibyendu K Sasmal
Jeong M Kim
Marcus J Taylor
P2860
P304
P356
10.1126/SCIENCE.AAF1292
P407
P577
2017-03-09T00:00:00Z